Ga Liu

SEP 9, 2026 · JOURNAL ARTICLE

A dual-site oral nanovaccine programs anti-colorectal tumor immunity from small intestinal priming to large intestinal boosting

Nature Communications

This is a mechanistic proof-of-concept study in a preclinical model demonstrating a novel nanovaccine strategy; it lacks human data, phase classification, or clinical endpoints needed for stronger evidence grading.